German Centre for Cancer Registry Data, Robert Koch Institute, Berlin, Germany.
Haematology, Oncology and Tumour Immunology, Charité - University Hospital Berlin, Campus Benjamin Franklin, and Max-Delbrueck-Centre for Molecular Medicine, Berlin, Germany.
Br J Haematol. 2017 Apr;177(2):226-242. doi: 10.1111/bjh.14530. Epub 2017 Jan 20.
The increased risk of subsequent primary malignancies (SPM) in survivors of adult-onset Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains a challenging clinical problem worldwide. The German cancer registry database, pooled from 14 federal states, was used to calculate the standardized incidence ratio (SIR) and excess absolute risk (EAR) of SPM in 128 587 patients registered with first primary HL/NHL between 1990 and 2012. Conversely, SIRs were also calculated for a subsequent HL/NHL following other first cancers. The risk of developing SPM was significantly increased over twofold for HL survivors (SIR = 2·14, EAR = 51·87 cases/10 000 person-years) and 1·5-fold for NHL survivors (SIR = 1·48, EAR = 55·23) compared with the general German population. For solid cancers, SIRs were significantly elevated (1·6- and 1·4-fold; respectively) and were highest (threefold) in patients below 30 years of age upon initial diagnosis. Overall, SIRs were consistently elevated for lip/oral cavity, colon/rectum, lung, skin melanoma, breast, kidney and thyroid. Significantly increased SIRs for oesophagus, stomach, liver, pancreas, testis, prostate, and brain/central nervous system were observed following NHL only. For certain SPM, SIRs remained significantly elevated more than 10 years following HL/NHL diagnosis. Positive reciprocal associations were demonstrated between HL/NHL and several solid cancers mentioned above; for some, common aetiological mechanisms seem plausible.
成人期霍奇金淋巴瘤(HL)和非霍奇金淋巴瘤(NHL)幸存者发生继发性原发性恶性肿瘤(SPM)的风险增加仍然是一个具有挑战性的全球临床问题。利用来自 14 个联邦州的德国癌症登记数据库,计算了 1990 年至 2012 年间首次确诊 HL/NHL 的 128587 例患者的 SPM 标准化发病比(SIR)和超额绝对风险(EAR)。相反,也计算了其他首次癌症后发生的 HL/NHL 的 SIR。HL 幸存者发生 SPM 的风险显著增加了两倍以上(SIR=2.14,EAR=51.87 例/10000 人年),NHL 幸存者增加了 1.5 倍(SIR=1.48,EAR=55.23)与德国普通人群相比。对于实体瘤,SIR 显著升高(分别为 1.6 倍和 1.4 倍),首次诊断时年龄在 30 岁以下的患者最高(三倍)。总体而言,唇/口腔、结肠/直肠、肺、皮肤黑色素瘤、乳房、肾脏和甲状腺的 SIR 持续升高。仅在 NHL 后观察到食管、胃、肝、胰腺、睾丸、前列腺和脑/中枢神经系统的 SIR 显著增加。HL/NHL 诊断后 10 年以上,某些 SPM 的 SIR 仍显著升高。HL/NHL 与上述某些实体瘤之间存在显著的正相关关系;对于某些疾病,共同的病因机制似乎是合理的。